ArticleJournal of orthopaedic surgery and research2025
Does halofuginone influence regeneration after peripheral nerve injury?
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHalofuginone is an antiprotozoal drug with antifibrotic and anti-inflammatory properties. The aim of our study was to determine the effects of halofuginone on nerve recovery in sciatic nerve injury and compare it with steroid treatment.
methodsThe left sciatic nerves of Sham subjects were exposed without intervention. The nerves of trauma animals were transected and sutured. In the methylprednisolone group and in the trauma group, after nerve transection and repair, 1 mg/kg methylprednisolone per day was administered intraperitoneally for seven days; in the halofuginone group and in the trauma group, after nerve transection and repair, 0.2 mg/kg halofuginone per day was administered orally by gavage for seven days. The rats were functionally evaluated at 4 and 8 weeks through walking path analysis. Pathological-morphometric, immunostaining-quantitative, and muscle weight measurements were performed at 8 weeks.
resultsCompared with the trauma group, the methylprednisolone and the halofuginone groups had better functional outcomes (p < 0.001). Statistically significant difference was found in comparisons of the pathological and immunostaining results of the methylprednisolone and halofuginone groups (Respectively, nerve diameter (p = 0.007) and edema (P = 0.009)).
conclusionHalofuginone positively contributed to recovery after sciatic nerve injury. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.